Paclitaxel-Eluting Versus Sirolimus-Eluting Stents in Diabetes Mellitus | Zendy

William M. Wolf | Zendy; Helen Vlachos | Zendy; Oscar C. Marroquin | Zendy; Joon S. Lee | Zendy; Conrad Smith | Zendy; William Anderson | Zendy; John Schindler | Zendy; Elizabeth M. Holper | Zendy; J. Dawn Abbott | Zendy; David O. Williams | Zendy; Warren K. Laskey | Zendy; Kevin E. Kip | Zendy; Sheryl F. Kelsey | Zendy; Suresh Mulukutla | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Paclitaxel-Eluting Versus Sirolimus-Eluting Stents in Diabetes Mellitus

Author(s) -

William M. Wolf,

Helen Vlachos,

Oscar C. Marroquin,

Joon S. Lee,

Conrad Smith,

William Anderson,

John Schindler,

Elizabeth M. Holper,

J. Dawn Abbott,

David O. Williams,

Warren K. Laskey,

Kevin E. Kip,

Sheryl F. Kelsey,

Suresh Mulukutla

Publication year - 2010

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.109.885996

Subject(s) - medicine , percutaneous coronary intervention , clopidogrel , cardiology , restenosis , diabetes mellitus , stent , sirolimus , myocardial infarction , aspirin , surgery , endocrinology

Diabetes is a powerful predictor of adverse events in patients undergoing percutaneous coronary intervention. Drug-eluting stents reduce restenosis rates compared with bare metal stents; however, controversy remains regarding which drug-eluting stents provides greater benefit in patients with diabetes. Accordingly, we compared the safety and efficacy of sirolimus-eluting stents (SES) with paclitaxel-eluting stents (PES) among diabetic patients in a contemporary registry.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research